Amphastar Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Amphastar Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $719.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $731.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $644.40M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $498.99M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $437.77M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $349.85M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $83.38M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $80.14M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $79.05M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $79.79M | Mar 16, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $60.40M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $57.92M | Mar 14, 2018 |
| FY2017 | Jun 30, 2017 | $65.19M | Mar 14, 2018 |
| FY2017 | Mar 31, 2017 | $56.67M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $63.54M | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $64.22M | Mar 14, 2018 |
| FY2017 | Jun 30, 2016 | $68.03M | Mar 14, 2018 |
| FY2017 | Mar 31, 2016 | $59.37M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $76.91M | Mar 15, 2017 |
| FY2016 | Sep 30, 2015 | $63.87M | Mar 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.06M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $373.86M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $351.12M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $248.86M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $199.74M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $143.34M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $33.38M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $35.25M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $32.39M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $30.90M | Mar 16, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $159.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $137.55M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $91.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $62.12M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.40M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($1.03M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $1.31M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $47.79M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $868.0K | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $205.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $196.99M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $107.50M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $69.89M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $10.95M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($39.0K) | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | ($8.62M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($1.27M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $15.38M | Mar 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $73.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $73.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $74.77M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $60.93M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $67.23M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $68.85M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $57.56M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $43.50M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $41.52M | Mar 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $213.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $183.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $89.18M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $97.99M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $57.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $41.76M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $38.19M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $39.21M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $38.56M | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $41.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $38.17M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $24.03M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $27.46M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $33.86M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $41.56M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $46.81M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $35.10M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $21.38M | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.51B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $741.99M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $671.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $631.24M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $586.97M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $513.56M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $451.07M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $427.74M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $840.49M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $845.17M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $873.49M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $213.33M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $226.01M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $182.51M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $159.44M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $149.20M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $117.34M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $98.48M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $445.52M | Mar 11, 2022 |
| FY2021 | Dec 31, 2020 | $402.31M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $381.37M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $332.44M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $333.74M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $329.26M | Mar 14, 2018 |
| FY2017 | Dec 31, 2015 | $295.51M | Mar 14, 2018 |
| FY2017 | Dec 31, 2014 | $281.86M | Mar 14, 2018 |
| FY2016 | Dec 31, 2013 | $251.55M | Mar 15, 2017 |
| FY2015 | Dec 31, 2012 | $233.44M | Mar 15, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.22M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.13M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $3.31M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $3.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $3.63M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $3.95M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $4.46M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $3.98M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $666.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $568.79M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $409.27M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $271.72M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $180.34M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $117.77M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $116.37M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $67.49M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $72.64M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $70.86M | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $151.61M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $144.30M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $156.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $126.35M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $92.64M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $73.69M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $86.34M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $65.59M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $72.35M | Mar 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $40.30M | Mar 15, 2016 |
| FY2014 | Dec 31, 2014 | $42.68M | Mar 26, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 16, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 16, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 47.62M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 48.07M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 48.11M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 47.71M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 47.50M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 46.58M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 46.63M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 46.62M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 46.25M | Mar 14, 2018 |